Irritable bowel syndrome (IBS) is the most common diagnosis in clinical gastroenterology, affecting an estimated 10% to 15% of the general adult population. IBS and chronic idiopathic constipation (CIC) are disorders of gut-brain interaction, that are common, debilitating, often misunderstood, and a challenge to diagnose and manage. Treatment delays are rampant in patients suffering with IBS and CIC, with many waiting more than three years before seeking treatment for their symptoms. Patients often rely on over-the-counter (OTC) medications or dietary changes to alleviate their symptoms, though for many patients, debilitating symptoms remain or even worsen.
As a chronic, debilitating condition, the need for collaborative care strategies is essential to facilitate the early identification of symptoms, initiation of care, and to optimize long-term management by continuously monitoring symptoms and incorporating stepwise treatment approaches when dietary changes and over-the-counter (OTC) medications fail to provide symptomatic relief. The educational activities on the IBS/CIC Digital Hub have been designed to improve knowledge and performance leading to a confident, accurate diagnosis and prompt treatment of IBS/CIC to improve symptoms and patient quality of life.
American Gastroenterological Association institute guidelines on the pharmacological management of irritable bowel syndrome.
Weinberg DS, Smalley W, Heidelbaugh, et al. Gastroenterology. 2014;147:1146-1148.
Ford AC, Moayyedi P, Chey WD, et al. Am J Gastroenertol. 2018 Jun 27 doi:
10.1038/s41395-018-0084-x. [Epub ahead of print].
Chey WD. Gastroenterol Hepatol (N.Y.). 2018;14(5):309-312.
Dolan R, Chey WD, Eswaran S.
Expert Rev Gastronenterol Hepatol. 2018;12(6):607-615.
Drossman DA, Hasler WL. Gastroenterology. 2016;150(6):1257-1492.
Menees S, Chey WD. [version 1; referees: 3 approved]. F1000Research 2018, 7 (F1000 Faculty Rev):1029